Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) EBITDA Margin (2019 - 2023)

Historic EBITDA Margin for ADC Therapeutics (ADCT) over the last 5 years, with Q3 2023 value amounting to 18760.78%.

  • ADC Therapeutics' EBITDA Margin rose 187648600.0% to 18760.78% in Q3 2023 from the same period last year, while for Sep 2023 it was 3.89%, marking a year-over-year increase of 845000.0%. This contributed to the annual value of 2070430.86% for FY2022, which is 26867774900.0% up from last year.
  • Per ADC Therapeutics' latest filing, its EBITDA Margin stood at 18760.78% for Q3 2023, which was up 187648600.0% from 12819.58% recorded in Q2 2023.
  • ADC Therapeutics' EBITDA Margin's 5-year high stood at 18760.78% during Q3 2023, with a 5-year trough of 16095.5% in Q4 2019.
  • In the last 5 years, ADC Therapeutics' EBITDA Margin had a median value of 271.55% in 2023 and averaged 566.56%.
  • Its EBITDA Margin has fluctuated over the past 5 years, first plummeted by -4034300bps in 2021, then soared by 187648600bps in 2023.
  • Quarter analysis of 5 years shows ADC Therapeutics' EBITDA Margin stood at 16095.5% in 2019, then skyrocketed by 100bps to 36.16% in 2020, then crashed by -921bps to 369.08% in 2021, then surged by 102bps to 6.23% in 2022, then surged by 301203bps to 18760.78% in 2023.
  • Its EBITDA Margin stands at 18760.78% for Q3 2023, versus 12819.58% for Q2 2023 and 271.55% for Q1 2023.